Myofibroblasts (MFs), also defined as 'mesenchyme-like interstitial cells', are specialized cells originating in pathophysiological conditions and contributing to tissue repair during wound healing. They are responsible for granulation tissue contraction and soft tissue retractions. Their main activities are the production and modification of the extracellular matrix (ECM), the secretion of angiogenic and pro-inflammatory factors, and the generation of tensile force.
MFs can derive from resident cells or from circulating bone marrow-derived precursors ( Figure 1) .
In particular, MFs can derive from adventitial fibroblasts, but also from the transdifferentiation of smooth muscle cells (SMCs) resident in the tunica media as well as from endothelial cells (ECs), through an endothelial-mesenchymal transition (EMT) 1 ( Figure 1 ). The EMT process seems to be reversible, as the MFs have been proposed also to transdifferentiate into an endothelial-like cell as well as into SMCs with a synthetic phenotype during intimal thickening. 2 It was once believed that ECs and SMCs arose from separate progenitor cells. However, subsequent in vitro studies have shown with increasing frequency that mature vascular endothelium has the capability to differentiate into smooth muscle-like phenotypes, expressing a-smooth muscle actin (a-SMA). 3 Recent studies claimed to show that EMT occurred also in vivo in different murine models of tissue fibrosis. 4, 5 In contrast with these observations, additional recent studies in murine models of kidney fibrosis based on lineage tracing techniques (i.e. transgene fluorescent proteins and b-galactosidase) showed that EMT does not contribute to kidney fibrosis in vivo, but that interstitial pericytes are a major source for MFs during fibrosis. 6 Consequently, caution should be used when analysing the EMT contribution to fibrosis and detailed studies are warranted to verify the occurrence of EMT in injured vascular tissue in vivo. Interestingly, some studies highlighted that MFs can derive from transdifferentiation of macrophages during the inflammatory process. 7 Vascular MFs can potentially differentiate also from circulating precursors, defined as fibrocytes and characterized by the expression of markers CD34, CD45, and collagen I (Col I). 8 Fibrocytes are mesenchymal progenitors expressing mixed antigens of haematopoietic stem cells (HSCs), monocytes, and fibroblasts. Upon in vitro stimulation with cytokines and growth factors, fibrocytes produce ECM components and matrix metalloproteinases (MMPs) and acquire a contractile phenotype, differentiating into cells identical to MFs. 9 Evidence for a contribution of fibrocytes in the context of vascular injury repair derive from different studies, including the observations obtained in a model of ovine carotid artery synthetic patch graft, revealing that the intimal hyperplasia (IH) is partially derived from circulating HSCs, with cells that, once mature, have the morphology of SMCs but the combination of both HSC and mesenchymal markers (CD34, CD45, vimentin, a-SMA, and Col I), known to univocally define the fibrocytes. 8, 10 These findings are in agreement with other data published in a very recent study, revealing that transplant vasculopathy correlates with circulating fibrocyte levels.
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The question remains of whether fibrocytes and MFs are distinct populations, as they share many common features, or whether MFs represent a more mature cell derived from fibrocytes during wound healing.
Activated MFs and SMCs share a number of markers including a-SMA, SM22, caldesmon, vinculin, and h-calponin. This is not surprising, since these two cell types have common functional properties. Conversely, SM-myosin heavy chain (SM-MHC) is weakly expressed in MFs, whereas the transcription factor smoothelin is considered as a SMC-specific marker. 12 Expression of a-SMA renders fibroblasts highly contractile and hallmarks MF differentiation. Of interest, SMCs and MFs use distinct transcriptional mechanisms for regulating a-SMA expression, 13 with the transcription factor RTEF-1-modulating a-SMA transcription in MFs, but not in differentiated SMCs, where this function is played by the transcriptional enhancer factor-1. Nevertheless, it should also be underlined that there are still some unresolved questions regarding the properties that distinguish SMCs from MFs and the relationships between these two cell types in physiology and disease.
MF differentiation pathways
Differentiation of MFs normally occurs during the wound healing process, under concomitant mechanical and biochemical signals ( Figure 1 ). Three major ultrastructural features discriminate MFs from quiescent fibroblasts in tissues: (i) bundles of contractile microfilaments; (ii) extensive cell-to-matrix attachment sites, and (iii) intercellular adherens and gap junctions. 14 In this context, a-SMA acts as a mechanosensitive protein that is recruited to stress fibres under high tension. Figure 1 Schematic depiction of the main pathways of MF origin, differentiation, and role in vascular remodelling. MFs can derive from resident or circulating precursors under concomitant mechanical and biochemical stimuli. The cytokine TGF-b1 is produced by injured tissue and is the main biochemical inducer of MF differentiation. The TGF-b1 dimer is secreted as part of a larger complex with LAP and LTBP-1. Under ECM stretching or proteolytic cleavage, the TGF-b1 dimer is released and its subsequent binding to the receptor complex TGF-b1RI:TGF-b1RII triggers the intracellular signalling leading to MF maturation, in conjunction with the production of the ED-A isoform of fibronectin through an alternative splicing mechanism. The ED-A Fn can exert a cooperative function with TGF-b1 to activate a-SMA expression in stress fibres of differentiating MFs, whereas proto-MFs contain stress fibres composed of only b-and g-actins. After tissue repair, MFs can undergo apoptosis or can survive and lead to tissue fibrosis and remodelling, depending on the kind and duration of the injury. Dotted line arrows indicate pathways not yet well established in vivo. a-SMA, a-smooth muscle actin; Ang II, angiotensin II; Col I, type I collagen; Col III, type III collagen; ECM, extracellular matrix; ED-A Fn, extradomain type A fibronectin; EMT, endothelial -mesenchymal transition; ET-1, endothelin-1; FAK, focal adhesion kinase; LAP, latency-associated peptide; LTBP-1, latent TGF-b1-binding protein 1; PDGF, platelet-derived growth factor; TGF-b1, transforming growth factor-b1.
The external stimuli and agents that are able to trigger the differentiation of MFs can be quite heterogeneous. Tissue injury, causing a loss of interaction between cells and ECM, can stimulate the formation of MFs aimed at a rapid wound healing.
TGF-b1 is a cytokine with cytostatic and pro-apoptotic effects on most target cells. TGF-b1 and the downstream Smad family of signal transducers play an important role in tissue fibrosis and ECM remodelling (Figure 2A) , as it induces MF differentiation through the induction of a-SMA expression, due to the presence of a TGF-b1 response element in the a-SMA promoter. 15 TGF-b1 is synthesized as a precursor complexed with the latent TGF-b1-binding protein (LTBP) in the ECM (Figure 1) . TGF-b1 is activated when LTBP is removed extracellularly via proteolytic cleavage or through a mechanical stress with the mediation of different integrins. 16 Activated TGF-b1 binds to a heterodimeric receptor complex composed by two subunits, endowed with a tyrosine kinase activity ( Figure 2) . TGF-b1 has the ability to control cell adhesion and migration by modulating the adhesion molecule repertoire 17 and the synthesis of ECM components such as fibronectin (Fn) and collagen. 18 Furthermore, ECM can influence TGF-b1 expression, suggesting a feedback loop in vivo between these two elements. 19 Fn is a dimeric glycoprotein widely distributed in the plasma and in ECM. Fn polymorphism is due to the alternative splicing of the type III segments ED-A, ED-B, and IIICS. In vitro, TGF-b1 preferentially promotes the accumulation of the ED-A Fn isoform. 20 It has been demonstrated that ED-A probably induces a conformational change of Fn, which in turn increases the accessibility of the amino acid sequence RGD to interaction with the integrin a5b1, 21 generating intracellular signals in a conformational sensitive manner. The ED-A Fn can thus exert a cooperative function with TGF-b1 to activate a-SMA expression in differentiating MFs. For what concerns the intracellular pathways triggered by TGF-b1, this cytokine is able to act on several cell types, through distinct pathways, leading to different phenotype switches, including the transition to MFs (Figure 2) .
The final effect of TGF-b1 on the vascular tissue depends on the levels of the cytokine, on the relative cellular composition in the vascular wall, and on the presence of mutations affecting the function of the mediators in the different pathways triggered by TGF-b1.
Some of the pathways triggered by TGF-b1 and leading to tissue fibrosis and/or MF differentiation are summarized in Figure 2 . TGF-b1 has been first demonstrated to induce MF differentiation through a Smad-dependent pathway. 22 In more detail, TGF-b1 Figure 2 Schematic depiction of selected TGF-b1 alternative signalling pathways, leading to the activation of pro-fibrotic genes (A-C ) or to the ECM degradation (C and D), respectively. (A) TGF-b1 homodimer binds to the TGF-b1RII that is autophosphorylated. Phosphorylated TGF-b1RII recruits and phosphorylates TGF-b1RI, whose kinase activity in turn phosphorylates Smad2 and 3 (R-Smads). Smad3 binds to Smad4 and translocates into the nucleus, to interact with a variety of transcriptional co-activators (e.g. CBP/p300) or co-repressors (e.g. SnoN) to regulate the expression of specific genes, with particular reference to the activation of pro-fibrotic genes (e.g. Col I, CTGF). (B) TGF-b1 can exert biological effects through Smad-independent downstream pathways, involving the activation by PI3K of PAK2 and, subsequently, of the cytoplasmatic c-Abl, leading to fibroblast proliferation. PI3K can activate also Akt and subsequently mTOR, leading to fibroblast proliferation. These pathways have been hypothesized to interact with the canonical Smad-dependent pathway, leading to MF differentiation of the increased number of fibroblasts. (C) TGF-b1 can exert biological effects through Smad-independent downstream pathways, involving the activation of p38MAPK, JNK, ERK1/2, and protein kinase C. (D) TGF-b1 canonical signalling can switch to a non-canonical ALK1/Smad1/5/8 pathway, leading to vascular aneurysm, as highlighted in a model of thoracic aorta aneurysm induced in mice. 26 This pathway remains to be demonstrated in patients. c-abl, abelson non-receptor tyrosine kinase; CTGF, connective tissue growth factor; MAPK, mitogen-activated protein kinase; mTOR, mammalian target of rapamycin; PAK2, p21-activated kinase-2; PI3K, phosphatidylinositol 3-kinase.
Myofibroblasts in vascular remodelling binds to the heteromeric serine-threonine kinase receptors II (RII) and I (RI), leading to the phosphorylation of Smad2 and 3 (R-Smads), oligomerization with Smad4, nuclear translocation and activation of distinct transcription programmes, leading, among others, to the production of ECM proteins and tissue inhibitors of metalloproteinases (TIMPs) (Figure 2A ). Alternative non-canonical Smad-independent pathways has been also identified in fibroblasts, based on signal transduction from TGF-b1 receptor complex to the nucleus through the mediators PI3K, PAK2, Akt, c-Abl, and mTOR 23 ( Figure 2B ). This pathway leads to fibroblast proliferation and hence to tissue fibrosis, but it may not be required for MF differentiation.
Another pathway triggered by TGF-b1 is based on the activation of different mitogen-activated protein kinases (MAPK) ( Figure 2C ) that, according to the recent and preliminary studies, is involved in MF differentiation 24 or aortic aneurysm development. 25 Finally, data obtained in a model of thoracic aorta aneurysm induced in mice aorta allowed to propose a novel TGF-b1-induced pathway, in which signalling is switched from a TGF-b1RI/Smad2-dependent response to an ALK1/Smad1/5/8 response, enhancing ECM degradation ( Figure 2D ).
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Some studies revealed that TGF-b1 may differentiate its biological effects also through a modulation of the RI to RII ratio. 27 Angiotensin II (Ang II) is able to induce MF differentiation through the nicotinamide-adenine dinucleotide phosphate [NADP(H)] oxidase generation of reactive oxygen species (ROS) and the activation of p38MAPK and JNK signalling. 28 Endothelin-1 (ET-1) can also induce differentiation to MFs of cultured fibroblasts through the ET-A receptor. 29 Moreover, both Ang II and ET-1 are able to increase the expression and the release of TGF-b1 ( Figure 1 ).
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Novel pathways triggered by TGF-b1 and leading to tissue fibrosis or degradation are continuously identified. Additional studies are necessary to address the role of the Smad-and non-Smad-mediated signalling in MF differentiation and function.
MF ultimate fate
The fate of recruited/activated MFs in injured tissue may ultimately determine whether normal healing occurs or progression to endstage fibrosis ensues ( Figure 1) .
For what concerns the question whether MF differentiation is terminal or reversible, several studies demonstrated a down-regulation of a-SMA in cultured differentiated MFs in response to distinct factors, including TGF-b1 antagonists, growth factors, and cell density, without evident increased apoptosis. Myocardin, an essential target of TGF-b1 during MF differentiation, is able to repress its own expression in fibroblasts with a negative feedback loop that could allow the reversibility of fibroblast-MF phenotypic conversion. 31 In vivo, however, the reversal of MFs has not been detected, whereas massive apoptosis normally occurs after wound healing. 32 If this not happens, MFs increase in number and induce marked remodelling and tissue chronic fibrosis. The combinatorial effects of reduced growth factor expression, increased ECM turnover, and nitric oxide (NO) generation may set the stage for triggering MF apoptosis during the resolution of tissue repair.
14 Alternatively to growth factor signals, two mechanisms are conceivable to account for MF disappearance at the end of physiological tissue repair: cell release from stress and increased formation of cell -cell contacts. In fact, it has been hypothesized that in properly repaired tissue, the ECM regains its original mechanical properties and returns to stress-shield the resident fibroblasts. 33 The mechanisms that link stress release to induction of apoptosis are probably similar to those that control fibroblast to MF transition, i.e. stress perception pathways involving cell -ECM junctions. Cell -cell contacts and cadherins, other than cell -ECM contacts, have been demonstrated to be also involved in the transmission of survival signals in MFs, as the formation of homotypic cadherin junctions is a possible signal of the presence of MF accumulation in late granulation tissue. 34 Consistently, corneal MFs in dense culture decrease the expression of a-SMA and de-differentiate into fibroblasts, 35 probably due to contact-induced desensitization to TGF-b1. 36 MF apoptosis can be contrasted by the persistence of TGF-b1 expression and ECM deposition which promote the pro-survival/anti-apoptotic phenotype. 37 
Restenosis: characteristics and incidence
The treatment of atherosclerotic lesions can follow different revascularization strategies, including percutaneous transluminal angioplasty (PTA), stent deployment, cryoplasty, 38 rotational or directional atherectomy, and interposition of venous, arterial, or synthetic grafts. The interventional approach depends on the localization, number, and length of vascular lesions, as well as by patient characteristics and concurrent risk factors. Restenosis can be considered as an excessive wound healing reaction of the vessel submitted to revascularization procedures that leads to a new narrowing of the vascular lumen. Restenosis still represents the main limiting factor of the long-term success of revascularization procedures. Restenosis rates result to be higher in patients in the presence of risk factors such as hypertension, diabetes, 39 and hypercholesterolaemia, thus suggesting that the restenosis mechanisms in these patients can be different. The restenotic fibroproliferative disease is supported by the contribution of different phenomena, whose prevalence depends on the kind of revascularization procedure applied. The different factors contributing to vascular restenosis include constrictive remodelling, neointimal hyperplasia, and neoadventitia formation.
Neointimal hyperplasia is mediated by a cascade of inflammatory mediators and growth factors and is supported by the contribution of different cell types, including SMCs, MFs, and inflammatory cells. A detailed study revealed the existence of different subtypes of SMCs contributing to restenosis, and in particular of spindle-shaped SMCs in the tunica media, and of epithelioid SMCs in the neointima. 40 Remodelling consists in a spatial reorganization of elements of the vascular wall that can be compensative, leading to vessel lumen enlargement, or constrictive, leading to lumen narrowing.
In 1987, PTA technique significantly evolved with the introduction of bare-metal stents (BMS), with the aim of obtaining a long-term patency of the stenotic vascular lumen. After an initial optimism for the short-term results of clinical studies, long-term follow-up revealed a relevant percentage of patients incurring in in-stent restenosis, mainly related to inflammatory reaction and to neointima formation inside the stent. Nonetheless, improvements in strut configuration, thickness, and materials have enhanced deliverability and reduced vessel damage. Subsequent development of drug-eluting stents (DES), in which anti-proliferative drugs (e.g. paclitaxel, sirolimus, and the more recent zotarolimus and everolimus) 41 have been linked to the stent and gradually released, showed another long-term relevant side effect with respect to BMS, consisting in a delayed re-endothelialization after angioplasty, that leads to an excessive cell proliferation in the vascular wall and to thrombosis, thus requiring a more effective anti-platelet therapy. 42 Recent epidemiological studies report that the percentage of target vessel revascularization after DES or BMS deployment is 5.9 and 11.8%, respectively. 43 The bioabsorbable stent concept has recently emerged in response to the issues with metal stents, but, to date, no investigational device has successfully overcome issues such as relatively low radial force and variable degradation rates. 44 Despite the number of therapeutic strategies currently available for clinicians to inhibit or reduce restenosis, the complex multifactorial nature of restenosis frequently leads to a failure of the attempts for its prevention in patients. Innovative strategies, i.e. based on local gene delivery, targeted inhibition of gene expression, or on stem cellmediated repair of injured vessels, 45, 46 have been successfully tested in animal models of vascular stenosis. Additional studies will be necessary to verify the effectiveness of these strategies also in patients.
The role of MFs in arterial restenosis
The presence and the role of MFs in vascular (re)stenosis has been assessed in experimental animal models of revascularization, as well as in samples retrieved from patients during re-operation procedures. The large majority of studies highlighted the contribution of MFs to the neointima induced by vascular injury. Early studies reporting the presence and the role of MFs in animal models of vascular stenosis or in patients occasionally described these cells as 'activated mesenchymal cells' or SM-like cells. 47 One of the first descriptions of the presence of MFs in restenosis was reported for human thrombosed grafts. 48 The presence of MFs and SMCs in IH was determined on the basis of an ultrastructural analysis of the distal anastomotic regions of thrombosed saphenous veins and prosthetic grafts removed en bloc from patients during re-operation. A similar ultrastructural analysis was conducted in rabbit aortas replaced with either absorbable polyglycolic acid (PGA) or non-absorbable Dacron prostheses, revealing the presence of proliferating circumferentially oriented MFs in the PGA inner capsule. 49 An ultrastructural analysis of activated MFs in a model of porcine coronary angioplasty showed that these cells are characterized by bundles of microfilaments (stress fibres) as well as by dilated rough endoplasmic reticulum and large Golgi complex, which reflect the MF synthetic activity. 50 The presence and the detrimental role played by MFs in restenosis progression was subsequently supported by a study, demonstrating that intravascular irradiation of porcine coronaries submitted to balloon injury had a positive effect on remodelling through the reduction of a-SMA-positive cells in the adventitia and a general reduction of cell proliferation, without any increase in the apoptotic index. 51 MFs contribute not only to neointima, but also induce thickening of the tunica media, adventitial fibrosis, and remodelling of the ECM, a process that can contribute to late lumen loss after vascular injury.
Integrins are heterodimeric transmembrane cell surface receptors, required for both movement through and communication with the ECM. A study conducted in a model of rat vascular injury demonstrated that the remodelling process is based on the interaction between the a1b1-integrin expressed on the membrane of MFs and the collagen in the ECM. 47 More recently, also the a8b1 integrin, whose expression is induced by TGF-b1, has been hypothesized to contribute to constrictive remodelling mediated by MFs in a model of rat carotid angioplasty. 52 This hypothesis was supported by the observation that the inhibition of a8b1-integrin expression through the small interfering RNA technology impairs the MF contractility induced by TGF-b1. Many studies support not only the contractile activity of MFs in vascular restenosis, but also their intense synthetic activity. As a matter of fact, MFs produce not only TGF-b1, known to play an autocrine role on these cells, but also proteins of the ECM, including elastin in the neointima, type I collagen in the adventitia and neointima, 53 and tenascin, first in the adventitia and then in the neointima of rat and porcine arteries after angioplasty. 54 MFs are also involved in glycosaminoglycan synthesis and in early lipid retention in a model of porcine coronary artery angioplasty.
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The mechanisms at the basis of MF migration through the injured vascular wall involve a chemotactic recognition of MF receptors by specific chemokines and the synthesis of MMPs, in particular of MMP-1, but not of MMP-2. 56 In this context, the increased expression of syndecan-4 and its peculiar localization after rat carotid angioplasty (initially in the adventitia and later in the neointima), accompanied by its shedding induced by the mechanical stretch, was hypothesized to be correlated with the activation of MF migration from the adventitia to the neointima. 57 Ang II is among the factors that enhance MF migration from the adventitia to the neointima. This process is mediated by the increase in the VEGF receptor Flt-1 via the Ang II type 1 (AT1) receptors. 58 These observations were subsequently integrated by a study conducted on rat MFs isolated from aorta, revealing that Ang II plays a concentration-dependent action mediated by Nox4 via an H 2 O 2 -dependent pathway. 59 Nox4 is a subunit of the NADPH oxidase that interacts with the subunit p22-phox. A similar role in MF migration after vascular injury has been postulated for the analogue subunits Nox1 and Nox2, whose action is mediated by the superoxide anion and not by H 2 O 2 . 60 Of interest, Ang II-mediated ROS generation stimulates not only MF migration but also their differentiation, through a pathway based on the concerted action of AT1 receptors, p38MAPK and JNK. 28 Altogether, these data confirm the existence of a link between ROS production by NADPH oxidase after vascular injury and MF migration and differentiation. Among the most frequently applied techniques to highlight the migration of proliferating MFs from the adventitia to the neointima is the 'pulse' BrdU labelling of proliferating cells in models of vascular injury, and more precisely the time-dependent and combined immunohistochemical detection of BrdU-and a-SMA-positive cells after injury. This approach has been applied by two independent laboratories in models of porcine severe balloon injury of coronary arteries leading to increased neointima formation. 53, 61 Both these studies revealed that the formation of mature MFs in the adventitia requires some days after injury and that cell proliferation starts early in the adventitia after endoluminal injury, whereas only a few proliferating cells were present in the tunica media 2-3 days after injury. Another frequently applied technique to track the MF movement in the vascular wall after injury is the transfection of injured vessels with a replication-defective adenovirus containing the gene encoding the nuclear b-galactosidase. Harvesting of vessels at different time points after injury and X-gal staining of vessel cross-sections allows the analysis of cell migration through the vascular wall. This approach has been applied in a model of rat vein-to-artery graft 62 and in a model of rat carotid balloon angioplasty, 63 confirming the progressive migration of MFs from adventitia to neointima. Alternatively, adventitial cells have been labelled with a long-life fluorescent dye (PKH26) through a bathing of the arteries in vivo immediately after angioplasty. 64 Finally, a strategy based on perivascular seeding of syngenic adventitial fibroblasts transfected with the b-galactosidase reporter gene has been applied in a model of rat carotid angioplasty. 65 Some of these labelling and tracking techniques are exposed to criticism, as the results they provide could be not conclusive. For example, the BrdU labelling/tracking of proliferating cells provides information about the proliferative and migratory status not only of adventitial cells, but also of medial SMCs and of other cells, even if associated with immunohistochemical detection of a-SMA. In addition, the use of syngenic adventitial fibroblasts could bias the results, as the cultured fibroblasts could have different migratory properties in comparison to the resident cells and they could also elicit an immune response possibly affecting their action, as already discussed elsewhere. 64 MFs contributing to negative remodelling and neointima formation after vascular injury are usually described as deriving from resident adventitial fibroblasts. Nonetheless, this is a reductive point of view, as MFs have been depicted, since their discovery and characterization, as potentially deriving from a large panel of cell precursors. In the context of vascular injury, infiltrating MFs can derive also by circulating precursors isolated from buffy coat preparations from peripheral blood. 66 This observation is consistent with the finding that 5% of cells in neointima in a porcine model of thermal vascular injury co-expressed a-SMA and SWC3, a macrophage-specific antigen. 67 The studies described above are in contrast with others revealing that adventitial MFs differentiate after vascular injury but do not substantially contribute to neointima proliferation. 64, 68 In particular, the study conducted by Maeng et al. in a model of rabbit iliac artery angioplasty, based not on the labelling and tracking of adventitial cells positive to a-SMA, but on the immunohistochemical detection of smoothelin, considered as an univocal marker of SMCs, revealed that at late follow-up, 82% of intimal cells were smoothelin-positive, indicating that adventitial MFs play no major role in neointima formation. These discrepancies could be related to the different models of vascular injury, to the structure of the arteries, to the rupture of the elastic laminae, to the medial breaking (that could facilitate the migration of adventitial cells to the intima), and to the techniques used for the analysis of cell migration and identity. 64 Indications for the presence and the relevant role of MFs in the stenotic vasculature derive also from the analysis of specimens deriving from vein stenosis in dialysis, accompanied by the formation of a thrombus. Vascular access dysfunction is one of the most important causes of morbidity in the haemodialysis population in the USA 69 and, consequently, the analysis of the mechanisms leading to vein stenosis in these patients is of particular relevance. In this context, it has been demonstrated that cells in the thrombus show the phenotypic features of MFs, without any evidence of SM-MHC or smoothelin immunostaining. Similar results have been obtained in a model of catheter injury of rabbit jugular veins, 70 whereas the presence of MFs has been suggested in the venous neointimal hyperplasia in tissue samples collected from the graft-vein anastomosis of stenotic polytetrafluoroethylene (PTFE) grafts during surgical revision 69 and, subsequently, in a model of pig artery-vein PTFE graft stenosis. 71 To our knowledge, the only study that specifically addressed the analysis of the role of MFs in in-stent restenosis has been recently conducted in porcine coronary arteries submitted to stent deployment after the local application of an adenovirus expressing the ectodomain of the TGF-b1 type II receptor, revealing that the blockade of TGF-b1 does not reduce the stent-induced neointima but it stimulates vascular inflammation and the associated pathological changes that may potentially aggravate the lesion progression. 72 These data suggest that in the porcine model of in-stent restenosis, the antiinflammatory action of TGF-b1 probably prevails with respect to its pro-fibrotic activity.
Thoracic aortic aneurysms: clinical relevance and pathogenesis
Aneurysms are the major diseases affecting the thoracic aorta and represent the 13th leading cause of mortality in the USA; the incidence of thoracic aortic aneurysm (TAA) is estimated to be 5.9/ 100 000/year, a rate that is increasing with improvements in screening, as well as advancements in imaging methods. 73 An aortic aneurysm is defined as a dilatation of the vessel reaching a diameter at least 1.5 times greater than the expected normal diameter for that tract. 74 The most commonly involved tract is the ascending aorta (40% of cases), followed by the descending thoracic aorta (35%), the arch (15%), and the thoraco-abdominal aorta (10%). Risk factors include male sex, advanced age, smoking, hypertension, chronic obstructive pulmonary disease, and coronary artery disease: although these risk factors are shared with atherosclerosis, many TAAs occur in the complete absence of plaque deposition. 75 The most dreaded complications of TAA include dissection, which may lead to arterial occlusion and end-organ ischaemia, and rupture, which is almost invariably fatal. 76 Surgical treatment is the only resolving option for most forms of TAA. Aneurysm development results from an imbalance between lysis and synthesis of ECM components mainly in the medial layer, determining a medial degeneration, mainly characterized by SMC loss, elastin breakdown, and accumulation of mucopolysaccharides in cyst-like structures. An unknown number of environmental and genetic etiological factors may alternatively trigger the process of ECM remodelling, ultimately leading to the loss of the elastic function and of the tensionbearing properties of the vessel wall. However, the details on causative factors and on the mechanisms by which they cooperate in the development of TAAs are still poorly known, due to the limited availability of human tissue samples representative of the early lesions rather than of end-stage disease. To overcome this issue, experimental models have been set up to reproduce and describe the developmental steps of either idiopathic or syndromic forms of TAA; 77 however, the applicability of the results obtained in animal models of TAA to the human setting may be limited in this field. 78 The paradigmatic Marfan syndrome, accounting for 5% of all TAAs, 79 is an inherited systemic disorder characterized by cardiovascular, skeletal, and ocular abnormalities, with an autosomal dominant inheritance pattern with variable penetrance. Other known inherited syndromes account for only 20% of all cases of aortic aneurysms, 80 whereas the majority of patients are currently categorized as affected by 'idiopathic' TAA.
The primary defect in Marfan's syndrome affects the fibrillin-1 gene (FBN1): fibrillin is a component of the microfibrils that act as a scaffold for elastin fibre assembly and that connect SMCs to the elastic lamellae. 78 Therefore, its mutations result in a disarray of elastic fibres and in the loss of normal ECM -cell signalling, with subsequent SMC modulation to the synthetic phenotype and overproduction of ECM components and ECM-degrading enzymes, especially MMPs 2 and 9, leading to massive elastolysis. 81 A variety of corollary phenomena have been described beside this main pathogenetic sequence for Marfan's aortic disease, including the increased TGF-b1 signalling, presumably derived from reduced sequestration of the latent form in the ECM by LTBP-fibrillin binding. 82 Consistently, an increase in tissue levels of TGF-b1 and in Smad2 signalling has been found in aortic specimens from Marfan's patients, without an increase in TGF-b1 mRNA expression. 83 Other known inherited TAA syndromes include the Ehlers-Danlos syndrome, determined by a mutation in the type III pro-collagen gene (COL3A1), conditioning an insufficient collagen networking, 84 and the Loeys -Dietz syndrome, a recently described autosomal dominant syndrome with heterozygous mutations in the genes coding for TGF-b1 receptors 1 and 2 and characterized by an enhancement of TGF-b1 signalling within the aortic wall. 85 Only few of the nonsyndromic TAAs are classifiable as familial/inherited TAAs, generally transmitted in an autosomal dominant manner with decreased penetrance and variable expression; known involved mutations concern genes coding for a-SMA, SM-MHC, and TGF-b1 receptors. 80 More relevant from an epidemiological point of view, although relatively less clinically aggressive, non-syndromic sporadic TAAs remain an obscure entity as regards their aetiology. These are usually characterized by a more localized dilatation compared with syndromic forms, with slower rates of progression. 80 However, some forms may stand midway between common sporadic and classical syndromic forms, both in terms of clinical manifestations and of pathogenesis: this is typically the case of TAAs associated with congenital bicuspid aortic valve (BAV), the most frequent cardiac malformation, affecting 1-2% of the live births and predisposing to an increased risk of TAAs and dissections at a younger age than in the general population. 86 Several studies highlighted quantitative and qualitative differences between BAV-associated aortopathy and the other forms of aortic medial degeneration, including a unique portfolio of MMPs, 87 thinner elastic lamellae, earlier occurrence of SMC apoptosis, 88 lesser inflammatory infiltrates, and activation of different signalling pathways, e.g. a differential expression of PKC isoforms 87 and a lower level of endothelial NO synthase. 89 The setting of BAV adds complexity to the attempt to define a pathogenetic hypothesis for TAAs, because the BAV is believed to yield abnormal flow characteristics since birth, even in the absence of significant valve stenosis or regurgitation; 90 consequently, resident cells in the aortic wall are exposed to two possibly coexisting risk factors for the alteration of the vascular remodelling process, i.e. the hypothesized but still undetected congenital defect and the altered biomechanical environment secondary to subtle but longstanding haemodynamic derangement.
The emerging role of MFs in TAA
In the relatively recent efforts to gain an in-depth knowledge of the pathogenetic mechanisms underlying TAA development, the attention has been focused mainly on the role of SMCs and of the main effectors of ECM degradation. However, some discrepancies outstand among the results of different studies with regard to SMC behaviour in medial degeneration. In particular, although Ihling et al. 91 detected apoptosis of SMCs in medial degeneration samples from dilated or dissected aortas, Lesauskaite et al. 92 found no SMC apoptosis in aortas from patients with either TAA, aortic valve disease, or aortic dissection, as well as no significant reduction in cellular density or evidence of SMC phenotype switch. More recently, Tang et al. highlighted an increase in total medial area per vessel section and in a-SMA-positive cell density in TAAs compared with normal aortas, inferring that SMC proliferation must have occurred. However, Ki67 co-staining failed to confirm this hypothesis because many of the proliferating cells were revealed to be infiltrating leucocytes. 93 Also our group 88 has confirmed normal or increased cell density in both
TAAs and smaller diameter dilatations; however, Ki67 was not overexpressed compared with normal aortas, and TUNEL/a-SMA co-staining showed significant cell apoptosis compared with nondiseased aortas. Others have found a reduction of SMC density in specimens from dilated and dissected aortas compared with normal aorta, and attributed it, at least in part, to leucocyte-induced apoptosis. 94 The discrepancies concerning aneurysm cellularity may be due to several reasons, including: (i) heterogeneity of the enrolled patients, in terms of underlying disease and/or evolutional stage of TAA; (ii) local heterogeneity of cell density as well as of other signs of medial degeneration, 88 with possibility of a sampling site bias in some studies; and (iii) limited appropriateness of a-SMA alone as a marker of SMCs, as its expression is shared also by MFs. On the basis of the above considerations, a growing interest is gradually emerging for a possible role of MFs in TAA. In 2006, Nataatmadja et al. 95 reported for the first time the evidence of TGF-b1 overexpression in SMCs and fibroblasts from Marfan's patients, together with hyaluronan and a-SMA up-regulation, and proposed that fibrillin-1 mutations may in some way lead to increased TGF-b1 signalling and MF differentiation. Indeed, a-SMA expression by differentiated MFs may explain the increase in a-SMA+ cellularity observed in some of the studies mentioned above without evidence of proliferation. 88, 93 More recently, another study 83 claimed that levels of TGF-b1 isolated from tissue samples of Marfan-related, BAV-related, and non-syndromic TAAs were constantly increased in comparison to normal aortas: however, TGF-b1 mRNA was not increased, whereas both LTBP and its mRNA were over-expressed, indicating that an increased TGF-b1 storage in the ECM could be the cause for its greater availability. Since the changes above mentioned were observed in all three patient groups with different aetiology, MF activation could indeed be a feature of aneurysm progression, e.g. possibly caused by dilatation itself, rather than an upstream mechanism of causation.
Considering that the direct identification of cell types is often challenging, most authors have rather looked at the mediators of MF differentiation or of TGF-b1 signalling. The only study that has attempted to discriminate among cell types in the media layer through specific markers has been recently issued by Jones et al.
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They used a murine model of calcium chloride-induced TAA, highlighting a peculiar pattern of cell marker changes over time, indicating the emergence of a fibroblast-derived cell population expressing contractile proteins, namely MFs (Figure 3) . Together with the findings obtained in human samples by Gomez et al., 83 this observation may suggest that during TAA development, two contemporary phenomena occur: (i) an SMC phenotype switch (earlier) and apoptosis (later), both tending towards a loss of contractility in the aortic media, and (ii) a sort of compensatory increase in MFs that partially restores medial overall contractile property but concurrently participates in enhancing ECM proteolysis and deposition. Notably, both these phenomena may be explained by TGF-b1 stimulation of SMCs and fibroblasts, respectively, 22 with a possible co-participation, among other pathways, of Ang II signalling. 97 Indeed, an altered TGF-b1 signalling at both receptor and transcriptional level, with an increase in Smad2 but also in Smads 1, 5, and 8 (R-Smads), and a decrease in TGF-b1 receptor 1 and Smad4, has been highlighted by Jones et al. 26 Although the classical TGF-b1 signalling pathway, via receptor 1 phosphorylation by receptor 2 and subsequent activation of the R-Smad, leads to pro-fibrotic effects (Figure 2A) , the alternative pathways, like those involving the type 2 receptor in conjunction with ALK1, alternative to the classical receptor 1, and activating other kinases such as p38MAPK or ERK1/2, may yield opposite effects, including production and release of MMP-2, MMP-9, and MMP-13, plasminogen activator, and therefore ECM disruption 22 ( Figure 2D) .
A similar release of MMPs, stimulated by TGF-b1 but mediated by a p38MAPK pathway, has been obtained in vitro 98 ( Figure 2C ).
On the basis of the highlights from the above-reported experiences, our group is currently performing a gene expression analysis related to MF differentiation in human TAAs (BAV vs. tricuspid aortic valve vs. non-diseased aortas). Notably, we are including in the study only small-size dilatations (mean aortic diameter 3.7 -4.0 cm), in order to get a depiction of the early changes occurring during aneurysm development. Preliminary data showed so far: (i) increased TGF-b1 mRNA expression, unlike the study by Gomez et al., that investigated frankly aneurismal aortas, representative of more mature lesions; (ii) increased expression of the TGF-b1 receptor 2, while the subunit 1 consistent with the findings from the murine model 26 was down-regulated; (iii) decreased expression of ED-A Fn;
and (iv) increased expression of LTBP-1. Our results may suggest that non-genetic factors, such as undue haemodynamic burden, 99 may influence altered TGF-b1 signalling in the early development of aortic dilatation with a dysfunctional BAV.
Potential therapeutic strategies for MF inhibition
An enhanced understanding of the mechanisms and molecular pathways responsible for MF differentiation, synthetic activity, and migration could lead to the development of novel strategies aimed at halting the progression of restenosis, promoting the long-term patency of blood vessels. Since the MFs that participate to the negative remodelling of the vessel induced by vascular injury originate mainly from the adventitia, the local administration of potential therapeutic molecules targeted to this specific cell type should be easier. Among the potential strategies to limit MF activation and consequent fibrosis, the blockade of mediators of MF differentiation through specific monoclonal antibodies (Ab) is currently under investigation in different experimental models. 100 An alternative approach is based on the administration of the NH 2 -terminal peptide of a-SMA, able to inhibit the MF contractile activity, 101 thus providing the basis for a cytoskeleton-dependent therapy for fibrocontractive diseases. Another study revealed the reduction of adventitial fibrosis through a dimeric recombinant soluble TGF-b1 receptor II in rats submitted to carotid angioplasty. 102 Hepatic fibrosis is reduced in Smad3-null mice, 103 suggesting that the inhibition of the expression or activity of this target gene could be helpful also in other fibroproliferative diseases, including restenosis. Intravascular irradiation was found to have a positive effect on vascular remodelling induced by balloon overstretch injury through a reduced recruitment of MFs in the adventitia at the injury site, 104 Figure 3 Expression profiles of cell-specific markers in a murine model of TAA induced through the periadventitial positioning of a sponge soaked in 0.5 M calcium chloride solution: after an initial phase of marked decrease in a-SMA expression, supposed to be due to SMC apoptotic loss (caspasethus supporting the potential effectiveness of brachytherapy in the reduction of fibrosis in arteries submitted to haemodynamic procedures.
Alternatively, MF recruitment at the injury site could be interrupted by interfering with specific chemokine signalling involved in MF migration. Chemokines identified as pro-fibrotic mediators (e.g. CCL2/CCL3/CCL6), and hence as potential anti-fibrosis targets, have been recently summarized. 105 A strategy alternative to the blocking of pro-fibrotic chemokines could be the administration of cytokines with an anti-inflammatory and an anti-fibrotic role. In this context, IL-10 has already been tested as an anti-fibrotic factor in experimental and clinical studies. 106 In our opinion, a potential therapeutic approach based on interference of MF contraction through the fusion peptide of a-SMA as proposed by Hinz et al. could be more feasible and specific than the blockade of MF mediators, as these molecules, and in particular TGF-b1, are involved in a plethora of functions, and consequently, their indiscriminate inhibition could be accompanied by relevant side effects. In this view, it has been recently demonstrated that the autocrine production of TGF-b1 in MFs derived from hypertrophic scars up-regulates the expression of the focal adhesion molecule Hic-5, which markedly reduces the growth of pathogenic MFs. Inhibition of autocrine TGF-b1 in these cells reverses this process and induces an increased proliferation of pathogenic MFs. 107 Moreover, TGF-b1 acts in a concentration-dependent manner, as it stimulates fibroblast and SMC proliferation and migration at lower levels, 108 while inhibiting cell proliferation at high concentration, and consequently, the potential therapeutic strategies acting on TGF-b1 levels should be finely regulated. As regards targeting MFs and TGF-b1 signalling for preventing progression of TAAs, the relative recent introduction of the concept of a possible role of these cells in aneurysm pathogenesis is the cause for the current lack of experimental studies proposing therapeutic applications. Only in abdominal aortic aneurysms, Dai et al. 109 have proposed endovascular gene therapy to induce local TGF-b1 over-expression, demonstrating that the pro-fibrotic and wound healing activities of this signalling pathway were able to stabilize the aneurysms, preventing dilative progression. However, it is well known that abdominal aortic aneurysms profoundly differ from TAAs in terms of pathogenetic mechanisms and so do the resident cells in the aortic media, which suggest that these results cannot be extrapolated from the abdominal to the thoracic setting. 110 In mouse models of Marfan's syndrome, it has been demonstrated that blocking TGF-b1 signalling by either neutralizing Ab or by the AT1 receptor antagonist losartan partially prevent and possibly reverse aortic root dilatation. It has also been shown that this effect does not relate to the reduction of haemodynamic burden on the diseased aorta by the anti-hypertensive action of losartan. 111 Therefore, a multicentre randomized clinical trial comparing losartan with b-blocker therapy in children and young adults with Marfan's syndrome and TAAs recently started. 112 The general enthusiasm for this first case of primary prevention of TAA will certainly motivate further efforts for a more in-depth investigation of the pathogenetic mechanisms also of non-syndromic TAAs.
Conclusion
An in-depth analysis of molecular and cellular mediators of restenosis and TAA is warranted to identify potential therapeutic strategies to reduce their recurrence in patients. Experimental and clinical data support the key role played by MFs in vascular restenosis. Increasing evidence highlights a role for MFs also in TAA. As a consequence, the development of safe, selective, and effective therapeutic strategies for MF limitation could be of great help to limit these pathophysiological processes. As MFs play an important role in wound healing, the challenge will be the development of potential therapeutic approaches that will not affect the global repair processes after vascular injury, but only the chronic deleterious effects of progressive fibrosis.
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